Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEBSep 20, 2024 · Sarclisa-VRd also met several secondary endpoints which demonstrated deep responses in this patient population: Approximately three-quarters (74.7%) of patients treated with Sarclisa-VRd achieved a complete response (CR) or better compared to 64.1% of patients taking VRd (OR 1.7; 95% CI: 1.097-2.5; p=0.0160).
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
WEB4 days ago · REGN. Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in ...
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
WEBMay 27, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activities.
Sanofi targets first-line myeloma as Sarclisa delivers trial win
WEBDec 7, 2023 · Sanofi's quiet Sarclisa chalks up a first-in-class win with eyes on a first-line multiple myeloma nod. In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal...
Press Release: ASCO: Sarclisa is first anti-CD38 to - GlobeNewswire
WEBJun 3, 2024 · ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3.
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
WEB4 days ago · Sarclisa made around $413 million in sales for Sanofi last year, a fraction of the $9.7 billion booked by J&J for Darzalex, so having a niche free of competition from its rival could translate to ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB4 days ago · Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM...
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible …
WEBSep 20, 2024 · Sarclisa was approved by the FDA in 2020 in combination with pomalidomide and dexamethasone for adults with multiple myeloma who received at least two prior therapies including lenalidomide and a proteasome inhibitor. In 2021, it was approved by the agency in combination with Kyprolis (carfilzomib) and dexamethasone to treat adults with ...